RxDoctor Payments Data

Wesley Jones, MD

Surgery · Greenville, SCNPI 1750300398

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,350 of the $16,778 with a category attached, or 73.6%. Boston Scientific accounts for 96.8% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $13,577, 8.5 times the $1,603 reported in 2019. Among surgery clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,778in general payments, 2019–2025

Across 69 payments — averaging $243.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$16K
  • Cardiovascular Systems Inc.$161
  • AbbVie$115
  • Penumbra, Inc.$109
  • Bard Peripheral Vascular, Inc.$102
  • Bolton Medical Inc$55

What the payments were for

  • Speaking & faculty fees$12,35074%
  • Travel & lodging$1,3938%
  • Food & beverage$3,03518%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,778 in reported general payments places this provider in the 90th percentile of 553 surgery providers in South Carolina.

See all surgery providers in South Carolina

Medicare billing

Part B allowed, 2024
$177,763
Medicare patients
305
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase62$197,297
ZenpepLipase/Protease/Amylase12$66,759
Sucralfate32$5,920
Oxycodone Hcl195$2,218
CholestyramineCholestyramine (With Sugar)14$1,472
Ondansetron OdtOndansetron72$1,337
Morphine Sulfate ErMorphine Sulfate43$1,112
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen43$1,053
Lactulose25$633
Megestrol Acetate26$628
Promethazine Hcl49$473
Hydromorphone Hcl27$352
Omeprazole30$289
Pantoprazole Sodium18$165
Lansoprazole13$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$115$197,29762 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 553 surgery providers in South Carolina.

Other surgery in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →